Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an independent educational grant from Astellas.
The purpose of this activity is to educate clinicians who may encounter rare and/or refractory IFIs on optimal diagnostic protocols, appropriate susceptibility testing, and optimal therapeutic selections for IFIs, based either on guideline recommendations or via improvisational therapeutic approaches as elucidated based on rare case examples given in the activity. Expert Kathleen Mullane, DO, PharmD, responds to clinical challenges and barriers presented by faculty, James Lewis, PharmD, and George Thompson, MD. These rounds are offered to learners as 3 fungal infection modules: Mucormycosis, Candidiasis, Aspergillosis. The activity features a set of short, effective, and connected lessons that present clinical information surrounding the challenges associated with treating rare and/or refractory invasive fungal infections.
This activity is intended for infectious disease specialists, transplant specialists, oncologists, hematologists, emergency room physicians, surgeons, and other members of the healthcare team, especially those in the community hospital setting.
Upon completion of this activity, participants will be able to:
Identify patients at risk for IFIs using clinical characteristics and diagnostic tests
Identify appropriate antifungal therapy based on patient factors, clinical presentation, and susceptibility testing
Compare and contrast pharmacokinetic/pharmacodynamic profiles and efficacy and safety of available antifungal agents
Conflict Of Interest Disclosure Policy
Guidelines require that participants in CME/CE activities be made aware of all financial relationships that may be perceived as affecting the presentation of the faculty member. ACHL ensures that all faculty and staff involved in the planning, development, and implementation of ACHL activities disclose relevant financial relationships and that conflicts of interest are resolved before the CME/CE activity occurs. Complete information will be provided to participants prior to the start of the educational activity.
Kathleen M. Mullane, DO, PharmD Professor of Medicine, Department of Medicine/Section of Infectious Diseases University of Chicago Attending Physician, Immunocompromised Host Infectious Diseases Service Internal Medicine/Infectious Diseases and Global Health University of Chicago Medicine Chicago, IL
Dr. Mullane discloses the following: Advisory Board: GSK, Chimerix, Merck, Scynexis Honorarium Recipient: Merck Protocol Committee: GSK, Chimerix, Merck
James Lewis, II, PharmD, FIDSA Infectious Disease Clinical Pharmacy Supervisor Co-Director of Antibiotic Stewardship, Department of Pharmacy Oregon Health & Science University Portland, OR
Dr. Lewis discloses the following: Consultant: Merck
George Thompson, MD Associate Professor of Medicine, Medical Microbiology and Immunology Division of Infectious Diseases University of California, Davis Sacramento, CA
Dr. Thompson discloses the following: Research Grant: Astellas, Cidara Therapeutics, Merck, Scynexis
Accredited Provider Disclosures
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: This activity discusses the use of mold-active azoles for prophylaxis and treatment of non-FDA approved organisms and in non-FDA approved clinical settings, as well as use of echinocandins for prophylaxis and in combination.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity will take approximately 1 hour to complete. To receive credit, participants are required to complete the pre-test, view the activity, and complete the post-test and evaluation. To receive credit, 75% must be achieved on the post-test. A certificate will be immediately available. There is no fee for the generation of the certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please call ACHL at (877) 444-8435, ext. 160.